Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.

$599
Posted in: Basal Insulin Sep 05 | 2019Sanofi Initiates New Toujeo vs. Tresiba T1DM CGM Study (inRange)Purchase Blast
$599
Posted in: Glucose Monitoring Sep 05 | 2019Livongo Stock Plunges After First Post-IPO Earnings Release (Q2 '19)Purchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other Sep 03 | 2019Biocon/Mylan Glargine CRL; BI/ZEAL Dual Agonist Moves to Ph2; Vertex Acquires SemmaPurchase Blast
Free
Posted in: Other Sep 03 | 2019FENIX to Host EASD Social Event on Monday Sept 16Access Free Blast
$599
Posted in: GLP-1RA, SGLT2i Sep 03 | 2019More Thoughts from DAPA-HF… Could Novo+Lexicon Really Happen?Purchase Blast
$599
Posted in: SGLT2i Sep 01 | 2019DAPA-HF is a Home Run, But Results Remain UnpublishedPurchase Blast
$599
Posted in: SGLT2i Aug 27 | 2019AZ's Farxiga CKD Development Receives Fast Track DesignationPurchase Blast
$599
Posted in: SGLT2i Aug 26 | 2019Invokana CREDENCE Filing Accepted by EMA; Dexcom Wins Patent Dispute with AgaMatrixPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Aug 23 | 2019Lilly Wins in Arbitration with AdociaPurchase Blast
$599
Posted in: Basal Insulin Aug 22 | 2019Biocon’s Glargine Facility Receives EU GMP CertificationPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Aug 20 | 2019Medtronic CY Q2 '19 (FY Q1 '20) Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, Glucagon, Other Aug 15 | 2019Zealand to Launch HypoPal in the US Without a Partner; Zealand Q2 '19 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other Aug 12 | 2019Novo: Updated FENIX Viewpoint; Novo Q2 '19 London Earnings UpdatePurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
